1.
Simon Lohse. Scientific inertia in animal-based research in biomedicine. Studies in History and Philosophy of Science Part A. 2021;89:41-51. doi:10.1016/j.shpsa.2021.06.016
Translation and validation
1.
Désirée H. Veening-Griffioen, Guilherme S. Ferreira, Wouter P. C. Boon, et al. Tradition, not science, is the basis of animal model selection in translational and applied research. ALTEX. 2021;38(1):49-62. doi:10.14573/altex.2003301
1.
Biotechnology Innovation Organization, Informa Pharma Intelligence, Quantitative Life Sciences. Clinical Development Success Rates and Contributing Factors 2011-2020.; 2021:34. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.
1.
Hubert Dirven, Gunn E. Vist, Sricharan Bandhakavi, et al. Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports. 2021;11(1):6403. doi:10.1038/s41598-021-85708-2
1.
Michael Balls. It’s Time to Include Harm to Humans in Harm–Benefit Analysis — But How to Do It, That is the Question. Alternatives to Laboratory Animals. 2021;49(5):182-196. doi:10.1177/02611929211062223
1.
Michael M. Webster, Christian Rutz. How STRANGE are your study animals?. Nature. 2020;582:337-340. doi:10.1038/d41586-020-01751-5
1.
Pandora Pound, Merel Ritskes-Hoitinga. Can prospective systematic reviews of animal studies improve clinical translation?. Journal of Translational Medicine. 2020;18:15. doi:10.1186/s12967-019-02205-x
1.
Stanley T. Parish, Michael Aschner, Warren Casey, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology. 2020;112:104592. doi:10.1016/j.yrtph.2020.104592
1.
Pandora Pound. Are Animal Models Needed to Discover, Develop and Test Pharmaceutical Drugs for Humans in the 21st Century?. Animals (Basel). 2020;10(12):2455. doi:10.3390/ani10122455
1.
Antje Schmidt-Pogoda, Nadine Bonberg, Mailin Hannah Marie Koecke, et al. Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Annals of Neurology. 2020;87(1):40-51. doi:10.1002/ana.25643